Theravance Biopharma, Inc. (TBPH) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of medicines, primarily YUPELRI (revefenacin) for COPD. The company is currently undergoing a significant strategic shift following the failure of its Phase 3 ampreloxetine clinical trial, leading to a wind-down of that program and an organizational restructuring to align resources with its commercial focus on YUPELRI.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $17.7 million | $15.4 million |
| Net Loss | $(4.9) million | $(13.6) million |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.27) |
| Operating Cash Flow | $73.3 million | $43.0 million |
| Cash, Cash Equivalents & Marketable Securities | $394.7 million | $111.5 million (Total cash & restricted) |
| Total Assets | $472.3 million | $485.6 million (Dec 31, 2025) |
| Long-Term Debt | $0 | $0 |
Note: The company reported no long-term debt. The "Future royalty payment contingency" liability of $32.8 million is treated as a debt financing but carries no interest expense in Q1 2026 due to the program wind-down.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% year-over-year to $17.7 million, driven by a 7% increase in YUPELRI net sales (implied 35% share) due to customer demand growth and improved net pricing.
- Expense Reduction: Total operating expenses decreased to $27.2 million from $29.8 million in Q1 2025.
- R&D Expenses: Decreased 49% to $5.8 million, primarily due to the winding down of the ampreloxetine CYPRESS trial and restructuring cost savings.
- SG&A Expenses: Decreased 4% to $17.7 million, reflecting lower employee-related costs and restructuring efficiencies.
- Restructuring Costs: The company incurred $3.6 million in restructuring expenses in Q1 2026 (non-existent in Q1 2025), consisting of $2.6 million in cash severance and $1.0 million in non-cash equity award modifications.
- Interest Income: Interest and other income increased 221% to $3.0 million, driven by higher cash balances from milestone payments received in late 2025 and early 2026.
- Cash Position: Cash and marketable securities increased significantly to $394.7 million, bolstered by a $25.0 million milestone from Viatris (Jan 2026) and a $50.0 million milestone from Royalty Pharma (Feb 2026).
Guidance, Outlook, and Risks
- Strategic Review: The Board's Strategic Review Committee is accelerating its evaluation of alternatives to maximize shareholder value, including a potential sale of the company, following the ampreloxetine trial failure.
- Restructuring Outlook: The company expects to reduce operating expenses by approximately 60% relative to 2025 levels, with full run-rate cost savings of ~$70 million realized by Q3 2026. Total estimated restructuring costs are $8.5 million to $11.5 million ($5-7M cash, $3.5-4.5M non-cash).
- Ampreloxetine Program: The Phase 3 CYPRESS study failed to meet its primary endpoint. The program is being wound down, and interest expense on the associated royalty contingency liability has ceased.
- TRELEGY Milestones: The company received a $50.0 million milestone payment in February 2026. Up to $100.0 million in potential milestones remain available for 2026 based on TRELEGY sales thresholds.
- Patent Litigation: All patent infringement litigation regarding generic versions of YUPELRI has been settled. Generic manufacturers have been granted royalty-free licenses to launch in the US on or after April 23, 2039.
- Liquidity: Management expects current cash resources to fund operations for at least the next 12 months.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and actual cost realization of the 50% workforce reduction and R&D wind-down to confirm the projected $70 million annual run-rate savings.
- Strategic Alternatives: Monitor updates from the Strategic Review Committee regarding the potential sale of the company or other value-maximizing transactions.
- YUPELRI Commercial Performance: Track YUPELRI sales growth and pricing dynamics to ensure revenue stability in the absence of new product launches.
- TRELEGY Milestone Triggers: Confirm GSK's TRELEGY sales performance against the thresholds required to trigger the remaining $100 million in potential 2026 milestone payments.
- Generic Competition Timeline: Note the 2039 generic launch date for YUPELRI in the US and assess the long-term revenue runway.